Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - WaferGen Bio-systems, Inc. | v233033_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 23, 2011
WaferGen Bio-systems, Inc.
(Exact name of registrant as specified in its charter)
|
Nevada
|
000-53252
|
90-0416683
|
||
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
7400 Paseo Padre Parkway
Fremont, CA 94555
|
94555
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code: (510) 651-4450
|
|
Not Applicable
|
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events.
On August 23, 2011, WaferGen Bio-systems, Inc. (the "Company") issued a press release indicating that it has delayed filing its Quarterly Report on Form 10-Q for the period ended June 30, 2011 beyond the five-day extension period provided by Rule 12b-25. The Company intends to file the Form 10-Q within the next two weeks. In order to complete its financial statements and other information contained in the Quarterly Report on Form 10-Q, the Company needs additional time to finalize valuation amounts and related accounting treatment of convertible preferred stock, convertible notes and warrants issued in May 2011 in the Company’s $30.6 million private placement financing. A copy of the press release issued by the Company is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release issued on August 23, 2011.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
WaferGen Bio-systems, Inc.
|
||
|
Date: August 23, 2011
|
By:
|
/s/ Don Huffman
|
|
Don Huffman
|
||
|
Chief Financial Officer
|
||